Abstract: The present application relates to new binder-drug conjugates (ADCs) of N,N-dialkylauristatins that are directed against the target C4.4a, to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for treating and/or preventing illnesses, and also to the use of these ADCs for producing medicaments for treating and/or preventing illnesses, more particularly hyperproliferative and/or angiogenic diseases such as, for example, cancer diseases. Such treatments may be practised as a monotherapy or else in combination with other medicaments or further therapeutic measures.

Abstract: The present patent application relates to novel binder-drug conjugates (ADCs) of N,N-dialkylauristatins directed against the target epidermal growth factor receptor (EGFR, gene ID 1956), effective metabolites of these ADCs, methods for producing these ADCs, use of these ADCs for treatment and or prevention of diseases as well as the use of these ADCs to produce pharmaceutical drugs for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic diseases such as cancer, for example. Such treatments may be administered as monotherapy or in combination with other pharmaceutical drugs or other therapeutic measures.

Abstract: The present application relates to new binder-drug conjugates (ADCs) of N,N-dialkylauristatins that are directed against the target C4.4a, to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for treating and/or preventing illnesses, and also to the use of these ADCs for producing medicaments for treating and/or preventing illnesses, more particularly hyperproliferative and/or angiogenic diseases such as, for example, cancer diseases. Such treatments may be practiced as a monotherapy or else in combination with other medicaments or further therapeutic measures.

Abstract: The present application relates to new binder-drug conjugates (ADCs) of N,N-dialkylauristatins that are directed against the target C4.4a, to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for treating and/or preventing illnesses, and also to the use of these ADCs for producing medicaments for treating and/or preventing illnesses, more particularly hyperproliferative and/or angiogenic diseases such as, for example, cancer diseases. Such treatments may be practised as a monotherapy or else in combination with other medicaments or further therapeutic measures.

Abstract: The present patent application relates to novel binder-drug conjugates (ADCs) of N,N-dialkylauristatins directed against the target epidermal growth factor receptor (EGFR, gene ID 1956), effective metabolites of these ADCs, methods for producing these ADCs, use of these ADCs for treatment and or prevention of diseases as well as the use of these ADCs to produce pharmaceutical drugs for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic diseases such as cancer, for example. Such treatments may be administered as monotherapy or in combination with other pharmaceutical drugs or other therapeutic measures.

Abstract: The present application relates to new binder-drug conjugates (ADCs) of N,N-dialkylauristatins that are directed against the target mesothelin, to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for treating and/or preventing illnesses, and also to the use of these ADCs for producing medicaments for treating and/or preventing illnesses, more particularly hyperproliferative and/or angiogenic diseases such as, for example, cancer diseases. Such treatments may be practised as a monotherapy or else in combination with other medicaments or further therapeutic measures.

Abstract: The present application relates to new binder-drug conjugates (ADCs) of N,N-dialkylauristatins that are directed against the target C4.4a, to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for treating and/or preventing illnesses, and also to the use of these ADCs for producing medicaments for treating and/or preventing illnesses, more particularly hyperproliferative and/or angiogenic diseases such as, for example, cancer diseases. Such treatments may be practised as a monotherapy or else in combination with other medicaments or further therapeutic measures.

Abstract: The goal of the invention is to increase the therapeutical activity of oncolytic NDV. This issue is solved by a Newcastle Disease Virus comprising a recombinant nucleic acid, wherein the nucleic acid codes for a binding protein that has a therapeutic activity when expressed by the virus-infected tumor cell. Binding proteins belong to the following group: A natural ligand or a genetically modified ligand, a recombinant soluble domain of a natural receptor or a modified version of it, a peptide-ligand, an antibody molecule and derivatives thereof or antibody-like molecules like ankyrin repeat molecules or derivatives thereof.

Abstract: The invention refers to a recombinant oncolytic RNA Newcastle Disease Virus for the treatment of a proliferative disease, comprising at least one transgene coding for an avian cytokine, wherein the recombinant oncolytic RNA Newcastle Disease Virus is obtainable from a velogenic or mesogenic oncolytic RNA Newcastle Disease Virus. Virus-mediated expression of the cytokine in the natural host cells leads to a reduced pathogenicity of the virus for avian species. Furthermore the virus genome can encode binding proteins, prodrug-converting enzymes or/and proteases. The selective expression of these molecules in virus-infected tumor cells increases the anti-tumor effect of the virus.

Abstract: Paramyxovirus from the group APMV3, APMV4, APMV5, APMV6, APMV7, APMV8, APMV9, Mapueravirus and Fer-de-Lance virus are described, which can be used for the production of a medicament for the treatment of tumors. The virus has a selectivity to kill human tumor cells but not human normal differentiated and human normal proliferating cells at the same dose. By genetic engineering the virus can be modified in such a way that one or more genes are added or are replaced by the homologous genes of a related paramyxovirus. By that method the anti-tumor activity of the resulting chimeric virus is enhanced compared to the parental virus.

Abstract: The goal of the invention is to increase the therapeutical activity of oncolytic NDV. This issue is solved by a Newcastle Disease Virus comprising a recombinant nucleic acid, wherein the nucleic acid codes for a binding protein that has a therapeutic activity when expressed by the virus-infected tumor cell. Binding proteins belong to the following group: A natural ligand or a genetically modified ligand, a recombinant soluble domain of a natural receptor or a modified version of it, a peptide-ligand, an antibody molecule and derivatives thereof or antibody-like molecules like ankyrin repeat molecules or derivatives thereof.

Abstract: A monobloc hollow shaft for transmitting torque, having two end portions, which, at their axial outer ends, are provided with shaft toothings for introducing torque, and having a central portion which, as compared to the end portions, has a smaller wall thickness, wherein, when torque is introduced via the shaft toothings, due to torsional forces a central part of the central portion of at least 25% of the length of the shaft is first of all uniformly plastically deformed.

Abstract: A driveshaft assembly has external profiled teeth at its end and a slide-on hub with a shaft bore with corresponding inner profiled teeth. A first securing mechanism form-fittingly engages a groove or thread radially cut into the profiled teeth and provided at the free end of the driveshaft and axially supporting the hub in the direction of the end of the driveshaft. External profiled teeth, which are provided at the driveshaft and which, when the hub is fully slid on to the driveshaft while being in contact with the first securing mechanism, extend axially relative to the shaft shank and beyond the length of the hub. A second securing mechanism, with a radially undisturbed profile of the profiled teeth, is supported on the run-out of the profiled teeth or on an adjoining conical face of the driveshaft. The second securing mechanism is plastically formed in-situ and axially supports the hub in the direction of the shaft shank of the driveshaft.

Abstract: A hub attachment assembly has a driveshaft with external splines at its shaft end, a slide-on hub with a shaft bore with corresponding internal splines, and an axial securing mechanism in the form of a resilient snap ring. The snap ring engages opposed recesses in the two sets of splines to couple the two parts together.

Abstract: A driveshaft for a motor vehicle has an approximately constant wall thickness and a changing outer diameter which extends analogously to the amplitude of the second basic vibration of the natural bending frequency. In this way it is possible to achieve a distribution of cross-sectional area which is functionally optimized and meets the respective strength requirements. At the same time, torsional stiffness values may be set as required and natural resonance frequency values may be varied. With help of this design it is possible to move the natural resonance frequency of the tubular shaft into a speed range of minimum external excitation energy.

Abstract: A wheel drive shaft assembly for a motor vehicle including two universal joints, at least one of which is a plunging joint to enable axial movement of the shaft assembly, with one of the universal joints further including a splined journal engaging into a wheel hub, wherein the axial length of the splined journal is smaller than the amount of axial shortening available in the shaft assembly by virtue of the plunging movement of the at least one plunging universal joint when the shaft assembly is built into the motor vehicle.

Abstract: A constant velocity ratio universal joint of plunging type, comprising an outer joint member (1), an inner joint member (2), facing pairs of tracks (3, 4) in the joint members receiving balls (5) for torque transmission, and a cage (6) constraining the balls and having first and second control surfaces (7, 9) with centers of curvature unequally off-set from the ball center plane I, in order to guide the balls to the bisect or plane, wherein the first control surface of the cage comprises two portions (7.sub.1, 7.sub.2). The first portion (7.sub.1) is part-spherical, and the second portion (7.sub.2) is a surface of revolution about the axis of the cage of an arc of radius of curvature less than the radius of curvature of the part-spherical portion (7.sub.1).

Abstract: The invention relates to a wheel bearing/constant velocity joint unit having a double row bearing 2 which has been provided with at least one inner bearing ring 12 which is separate from the wheel hub 1. The wheel hub and the outer part of the constant velocity joint are form-fittingly and non-rotatingly connected to each other by spur teeth. The spur teeth at the wheel hub are preferably produced by orbital pressing or orbital forging, and while the forming process takes place a collar is produced at the wheel hub which serves for axially tensioning the inner bearing rings, at least the one of the joint end.

Abstract: A wheel supporting assembly for a motor vehicle, comprising a wheel carrier member (1) with means for attachment to at least one suspension component, and a unit of hub member (16), universal joint member (21), and bearing with outer race (15) integral with or received in a bearing housing (3), secured to the wheel carrier member. The wheel carrier member affords a formation (2) open and undercut-free in a direction transversely of the rotational axis of the hub member, so that the hub member-bearing unit can be fitted radially to the wheel carrier member. The bearing housing of the unit is then held to the wheel carrier member by at least two fixing elements, particularly bolts, spaced from one another by a distance greater than an outer diameter of the bearing, which distance is preferably less than the size of a flange on the hub member to which a wheel is to be attached.

Abstract: A differential gear assembly wherein at least one constant velocity universal joint is integrated within the gear housing and wherein an outer joint member of the universal joint is designed as an outer bevel gear and is axially inwardly supported relative to the differential or planetary gears of the assembly and is outwardly supported relative to the differential carrier on a radial supporting face. The inner member of the joint is supported toward the outside on a counter face of the differential cage and/or toward the inside on a corresponding part of a second constant velocity universal joint or on a special supporting ring. Support of the joint inner part may be effected either directly or indirectly by means of a ball cage or a shaft journal, and the supporting ring is particularly suitable as a central supporting element if two constant velocity universal joints are integrated into the differential gear assembly.